MAPK3 and breast carcinoma: Whether the compounds that exerted inhibitory effects on leptin-stimulated breast cancer cell proliferation reduce the ERK1/2 phosphorylation was also tested.Although the pERK1/2 levels were lower in cells co-treated with both the compounds and leptin than in the cells that received only leptin, the difference was not statistically significant.